Item 2.02. Results of Operations and Financial Condition.




On July 28, 2021, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release
and is holding a conference call regarding its results of operations and
financial condition for the quarter ended June 30, 2021. The full text of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated by reference herein.
Various statements to be made during the conference call are "forward-looking
statements" under the securities laws, including, but not limited to, Vanda's
financial guidance for 2021, and statements regarding Vanda's commercial
products, plans and opportunities, as well as statements about Vanda's products
in development and the related clinical development and regulatory timelines and
commercial potential for such products. Words such as, but not limited to,
"believe," "expect," "anticipate," "estimate," "intend," "plan," "project,"
"target," "goal," "likely," "will," "would," and "could," or the negative of
these terms and similar expressions or words, identify forward-looking
statements. Forward-looking statements are based upon current expectations and
assumptions that involve risks, changes in circumstances and uncertainties.
Important factors that could cause actual results to differ materially from
those reflected in Vanda's forward-looking statements include, among others,
Vanda's assumptions regarding its ability to continue to grow its business in
the U.S., Vanda's ability to complete the clinical development and obtain
regulatory approval for tradipitant in the treatment of gastroparesis, the
prevalence of gastroparesis, Vanda's ability to successfully commercialize
tradipitant and Vanda's ability to complete the clinical development and obtain
regulatory approval for its other products in development. Therefore, no
assurance can be given that the actual results or developments anticipated by
Vanda will be realized or, even if substantially realized, that they will have
the expected consequences to, or effects on, Vanda. Forward-looking statements
made during the call should be evaluated together with the various risks and
uncertainties that affect Vanda's business and market, particularly those
identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk
Factors" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Vanda's Annual Report on Form 10-K for the
fiscal year ended December 31, 2020, as updated by Vanda's subsequent Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the
U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any
person acting on its behalf are expressly qualified in their entirety by the
cautionary statements contained or referred to herein. The information contained
in this Current Report on Form 8-K is intended to be considered in the context
of Vanda's filings with the SEC and other public announcements that Vanda makes,
by press release or otherwise, from time to time. Vanda cautions investors not
to rely too heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information conveyed on the conference call will be
provided only as of the date of the call, and Vanda undertakes no obligation,
and specifically declines any obligation, to update or revise publicly any
forward-looking statements made during the call after the date thereof, whether
as a result of new information, future events or otherwise, except as required
by law.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.


Item 9.01.        Financial Statements and Exhibits.



(d)Exhibits

Exhibit No.                                                Description

99.1                         Press release of Vanda Pharmaceuticals Inc. dated     July 28    , 2021.

104                        Cover Page Interactive Data File (embedded

within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses